NCT03941821

Glecaprevir/Pibrentasvir Real-world Study in China

The Efficacy, Safety and Long-term Prognosis of Glecaprevir/Pibrentasvir in the Treatment of Chronic Hepatitis C Patients in China--A Real-world Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 800 (estimated)
• Sponsor: Tongji Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy, adverse effect, short - and long-term outcomes of Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (non-cirrhotic or compensatory cirrhosis)in China through a real-world study

Detailed description

This study is a multi-center, prospective, real-world study, aiming to investigate the use of Glecaprevir/Pibrentasvir in routine clinical management of chronic hepatitis C patients and evaluate its effectiveness and safety across a heterogeneous population in China.Approximately 800 patients will take part in this study, 20 sites will be included which distribute in China's major cities, thus each site will enroll 40 patients.

Conditions

• Chronic Hepatitis c

Interventions

Type	Name	Description
DRUG	Glecaprevir/Pibrentasvir	Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment

Timeline

• Start date: 2019-06-30
• Primary completion: 2021-06-30
• Completion: 2022-06-30
• First posted: 2019-05-08
• Last updated: 2019-05-08